Search

everythinglearnresearchcommunity

for

Search:↓

Regenera Activa and exosome therapy are discussed for hair loss treatment, focusing on their effectiveness for regrowth, thickening, or reducing shedding. Users are seeking experiences and results from these treatments.

Hair regrowth in transfems is more effective due to hormonal changes, specifically estrogen, which keeps hair in growth phase longer. Treatments mentioned include anti-androgens, sex hormones, and DHT blockers like finasteride.

Exploring future hair loss treatments, including immunosuppressants for hair transplants and hair cloning, with a focus on leveraging research from other medical fields. Current treatments like finasteride and minoxidil are effective for most, but there's a call for more funding and innovation in the hair loss industry.

A 27-year-old male is using a minoxidil and finasteride spray for hairline recession and is considering other treatments like oral minoxidil, exosomes, PRP, or a hair transplant. Suggestions include microneedling, possibly with tretinoin, while another user suggests the hairline is fine and mentions body dysmorphia.

A user's experience with microneedling monotherapy and potential treatments such as finasteride, minoxidil, Stemoxydine, rosemary oil, peppermint oil, and RU58841 for reversing hair loss.

Exosomes are being discussed as a potential hair loss treatment, with some users skeptical about their effectiveness and stability. There is interest in different types of exosomes, including those derived from centella asiatica, and comparisons are made to other treatments like finasteride.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

A 22-year-old is frustrated with ongoing hair loss despite using treatments like topical minoxidil, finasteride, microneedling, oral dutasteride, and oral minoxidil. Their dermatologist suggests treating scalp inflammation with oral tretinoin and using exosomes for alopecia.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions a new hair transplant therapy approved by the government.

A 35-year-old man shared his hair transplant experience in Tijuana, Mexico, choosing Artline for 5,000 grafts at a lower cost than U.S. clinics. He plans to use topical minoxidil and possibly microneedling for better results.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

User seeks advice for regrowing temples, currently using Fin, oral Min, and dermarolling. Suggestions include improving scalp environment and considering RU58841 or dutasteride.

Users discussed using treatments like minoxidil, finasteride, dutasteride, and exosomes for hair loss. They reported thicker hair and reduced shedding, with some experiencing minor side effects.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

Hair loss and its potential treatments, such as minoxidil, finasteride, RU58841, dermarolling, and supplements. It discusses whether miniaturized follicles can be revived to grow again or must shed for new growth to appear.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

Hair cloning updates, with potential costs ranging from $200,000 to $350,000. Clinical trials may start in 2020, and some hope for cheaper options in Turkey or China.

A 22-year-old male is using Dutasteride, Minoxidil, RU58841, and Microneedling to treat hair loss and is wondering if he can regrow hair at his temples. Commenters suggest that he should continue the treatment as it takes time, with full results expected in 2-2.5 years.

The conversation discusses hair cloning progress and mentions treatments like Minoxidil, finasteride, and RU58841. Users also talk about hair transplants and their effectiveness.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

The conversation discusses the use of autologous exosomes for hair loss, questioning their effectiveness and seeking real user experiences. The user is skeptical about the treatment's legitimacy and is looking for honest feedback on its results.

A 32-year-old male is considering options to soften a dense transplanted hairline after experiencing accelerated hair loss and intolerance to finasteride and dutasteride, while using minoxidil. He is exploring partial electrolysis or laser treatments to achieve a natural look with a short buzz cut, avoiding a second transplant or scalp micropigmentation.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.

Adding exosomes to a treatment of dutasteride and minoxidil for hair loss increased hair count by 55% at 6 months and 46% at 1 year compared to the control group. The control group did not receive exosomes or PRP.

Dermatologists have differing opinions on hair loss treatments, with some using topical dutasteride, oral minoxidil, exosome therapy, PRP, and various other therapies. The user plans to use a topical solution of dutasteride, minoxidil, tretinoin, PRP, and LLLT.

Exosomes are being considered for hair regrowth, with some users reporting initial improvement. One user moved on to using dutasteride and oral minoxidil with positive results.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

A 24-year-old considering a hair transplant is currently using dutasteride for hair loss. They are unsure about proceeding with the transplant due to concerns about future hair loss and the need to shave their head for the procedure.